Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.43 |
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | MGAM | O43451 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 4/20 | 0.42 |
| ▸ | SI | P14410 | 4/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 4/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31254037 | 1.00 | ALDH1A1 (0.49) | ALDH1A1KDM4EMALT1MAPTCA2 | |
| Formaldehyde SCHEMBL27953583 | 0.95 | ALDH1A1 (0.49) | ALDH1A1KDM4EMALT1MAPTCA2 | |
| SCHEMBL30513267 | 0.86 | AKT1 (0.56) | ALDH1A1KDM4EMALT1MAPTESR2 | |
| SCHEMBL3184205 | 0.86 | AKT1 (0.56) | ALDH1A1KDM4EMALT1MAPTESR2 | |
| SCHEMBL282032 | 0.81 | ALDH1A1 (0.60) | ALDH1A1KDM4EMAPTCA2CA5A | |
| SCHEMBL9748973 | 0.80 | ALDH1A1 (0.41) | ALDH1A1KDM4EMALT1MAPTCA2 | |
| SCHEMBL7606467 | 0.80 | PKM (0.40) | ALDH1A1KDM4EMALT1MAPT | |
| SCHEMBL6797538 | 0.79 | PPARA (0.49) | — | |
| SCHEMBL23422992 | 0.79 | KDM1A (0.40) | MAPT | |
| SCHEMBL23746308 | 0.79 | HTR2C (0.46) | MALT1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250090554-A1 | A METHOD OF TREATING DEPRESSION BY IMMUNE MODULATION | MYND LIFE SCIENCES INC (CA) | 2025-03-20 | — | — | US | disclosed |
| EP-2970156-B1 | SUBSTITUTED BENZOXAZOLES AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2018-07-25 | — | — | EP | disclosed |
| CN-105492430-B | Substituted benzoxazole and its application method | 基因泰克公司 | 2017-10-10 | — | — | CN | disclosed |
| US-9771376-B2 | N-substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771376-B2 | N-substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9493429-B2 | Substituted benzoxazoles and methods of use thereof | GENENTECH, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-9493429-B2 | Substituted benzoxazoles and methods of use thereof | GENENTECH, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20160297754-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-10-13 | — | — | US | disclosed |
| US-20160297754-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-10-13 | — | — | US | disclosed |
| CN-105492430-A | Substituted benzoxazoles and methods of use thereof | GENENTECH INC | 2016-04-13 | — | — | CN | disclosed |
| US-20060287387-A1 | Fused tricyclic heterocycles useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-12-21 | — | — | US | disclosed |
| US-7144885-B2 | Fused tricyclic heterocycles useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-12-05 | — | — | US | disclosed |
| US-20050165042-A1 | Fused tricyclic heterocycles useful for treating hyper-proliferative disoroders | BAYER HEALTHCARE LLC | 2005-07-28 | — | — | US | disclosed |
| EP-1478639-A1 | FUSED TRICYCLIC HETEROCYCLES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2004-11-24 | — | — | EP | disclosed |
| WO-2003072566-A1 | FUSED TRICYCLIC HETEROCYCLES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-09-04 | — | — | WO | disclosed |
| EP-0230475-B1 | NOVEL UREA DERIVATIVES, PROCESSES FOR PRODUCTION THEREOF AND HERBICIDE | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1992-03-18 | — | — | EP | disclosed |
| US-4838924-A | NONPHYTOTOXIC | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1989-06-13 | — | — | US | disclosed |
| EP-0028449-B1 | CHROMANOL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION COMPRISING THEM | BEECHAM GROUP PLC (GB) | 1983-07-20 | — | — | EP | disclosed |
| US-4366163-A | Anti-hypertensive chromanol derivatives | BEECHAM GROUP LIMITED (GB) | 1982-12-28 | — | — | US | disclosed |
| EP-0028449-A1 | Chromanol derivatives, a process for their preparation and a pharmaceutical composition comprising them | BEECHAM GROUP PLC (GB) | 1981-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297754-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SNRPD2 | ALDH1A1 2216/4885KDM4E 2389/4885MALT1 398/4885 |
| US-20060287387-A1 | Fused tricyclic heterocycles useful for treating hyper-proliferative disorders | MKI67, CCNA2, CDK4 | ALDH1A1 973/4885KDM4E 3497/4885MALT1 129/4885 |
| US-20050165042-A1 | Fused tricyclic heterocycles useful for treating hyper-proliferative disoroders | MKI67, CCNI, PCNA | ALDH1A1 637/4885KDM4E 3721/4885MALT1 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.